多発性骨髄腫治療の市場規模、シェア、成長分析、治療タイプ別、投与経路別、疾患タイプ別、最終用途別、地域別 - 産業予測、2025～2032年

多発性骨髄腫治療の世界市場規模は2023年に248億米ドルと評価され、2024年の263億6,000万米ドルから2032年には429億8,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.3％で成長する見通しです。

世界の多発性骨髄腫治療市場は、骨髄を損傷し形質細胞の産生を阻害するこの血液学的がんの複雑な性質により、大きな成長を遂げています。この急成長の主な要因は、人口の高齢化とこの疾患の分子メカニズムに対する意識の高まりです。幹細胞移植、免疫調節薬、プロテアソーム阻害薬、モノクローナル抗体など、特殊で強力な治療法の開発における革新的な進歩も市場拡大に拍車をかけています。さらに、製薬会社は最先端の治療法や個別化医療戦略を生み出すための研究に多額の投資を行っており、競争の激しい情勢を助長しています。製薬会社、バイオテクノロジー企業、研究機関の協力により、特にモノクローナル抗体やCAR-T細胞療法など、効果的で副作用の少ない治療法のイントロダクションが推進されており、治療の選択肢における重要なマイルストーンとなっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

多発性骨髄腫治療市場規模：治療タイプ別

• 市場概要
• 化学療法
• 標的療法
• 免疫調節剤
• 幹細胞移植
• 放射線治療
• その他の治療の種類

多発性骨髄腫治療市場規模：投与経路別

• 市場概要
• 経口
• 非経口

多発性骨髄腫治療市場規模：疾患タイプ別

• 市場概要
• 活動性多発性骨髄腫
• くすぶり型多発性骨髄腫

多発性骨髄腫治療市場規模：最終用途別

• 市場概要
• 病院
• 専門クリニック
• 在宅ケアの設定
• その他のエンドユーザー

多発性骨髄腫治療市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Bristol Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Amgen Inc.（USA）
• Sanofi S.A.（France）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• GlaxoSmithKline plc（UK）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Celgene Corporation（USA）
• Karyopharm Therapeutics Inc.（USA）
• Ono Pharmaceutical Co., Ltd.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Genmab A/S（Denmark）
• Adaptive Biotechnologies Corporation（USA）
• Legend Biotech Corporation（China）
• MorphoSys AG（Germany）
• bluebird bio, Inc.（USA）
• Secura Bio, Inc.（USA）
• BeiGene, Ltd.（China）

結論と推奨事項

Global Multiple Myeloma Therapeutics Market size was valued at USD 24.8 billion in 2023 and is poised to grow from USD 26.36 billion in 2024 to USD 42.98 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The global multiple myeloma therapeutics market has experienced significant growth due to the complex nature of this hematological cancer, which damages bone marrow and disrupts plasma cell production. This surge is largely attributed to an aging population and heightened awareness of the disease's molecular mechanisms. Innovative advancements in the development of specialized and potent therapies, including stem cell transplants, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, have also fueled market expansion. Furthermore, pharmaceutical companies are heavily investing in research to create cutting-edge treatments and personalized care strategies, fostering a highly competitive landscape. Collaborations between pharma firms, biotech companies, and research institutions are driving the introduction of effective, low-side-effect therapies, notably monoclonal antibodies and CAR-T cell therapies, marking significant milestones in treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Therapeutics Market Segmental Analysis

Global Multiple Myeloma Therapeutics Market is segmented by Treatment Type, Route of Administration, Disease Type, End-use and region. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted therapy, Immunomodulating agents, Stem cell transplantation, Radiation therapy and Other treatment types. Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on Disease Type, the market is segmented into Active multiple myeloma and Smoldering multiple myeloma. Based on End-use, the market is segmented into Hospitals, Specialty clinics, Homecare settings and Other end-users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Myeloma Therapeutics Market

One of the key drivers of the global Multiple Myeloma Therapeutics market is the significant advancements in treatment options. Recent discoveries in innovative therapies, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs), have proven to be highly beneficial. These cutting-edge medications are designed to specifically target cancer cells while minimizing harm to healthy cells, resulting in improved treatment efficacy. This progress has led to higher patient survival rates and enhanced quality of life following treatment. As researchers and pharmaceutical companies continue to develop these novel therapies, they further propel the growth and potential of the multiple myeloma therapeutics market.

Restraints in the Global Multiple Myeloma Therapeutics Market

The Global Multiple Myeloma Therapeutics market faces significant restraints, primarily due to the high costs associated with treatment options. Despite advancements that have enhanced patient outcomes through the introduction of various innovative therapies, the steep price tags attached to these treatments can create barriers for patients, particularly those in economically challenged regions or with limited access to healthcare services. This financial obstacle may discourage the adoption of state-of-the-art therapies, ultimately restricting the market's growth potential. Consequently, addressing affordability and accessibility is crucial to ensure that promising treatment options reach the patients who need them the most.

Market Trends of the Global Multiple Myeloma Therapeutics Market

The Global Multiple Myeloma Therapeutics market is witnessing a significant shift towards advancements in targeted therapies and immunotherapies, reflecting a broader trend of precision medicine in oncology. As traditional chemotherapy presents limitations in efficacy and adverse effects, pharmaceutical companies are increasingly investing in developing innovative treatments that specifically target malignant cells while preserving healthy tissues. This focus includes the creation of monoclonal antibodies and specialized agents designed to inhibit myeloma cell proliferation. Furthermore, cutting-edge immunotherapy approaches, such as CAR-T cell therapy, have demonstrated promising results in clinical trials, offering patients more personalized and effective treatment options, thus propelling market growth and investment in novel therapeutic modalities.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Myeloma Therapeutics Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted therapy
• Immunomodulating agents
• Stem cell transplantation
• Radiation therapy
• Other treatment types

Global Multiple Myeloma Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Multiple Myeloma Therapeutics Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Active multiple myeloma
• Smoldering multiple myeloma

Global Multiple Myeloma Therapeutics Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty clinics
• Homecare settings
• Other end-users

Global Multiple Myeloma Therapeutics Market Size & CAGR (2025-2032)

• North America (Treatment Type, Route of Administration, Disease Type, End-use)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, Disease Type, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, Disease Type, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, Disease Type, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, Disease Type, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Legend Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MorphoSys AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Secura Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations